Protease inhibitor ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 265 | Lipodystrophy | 6 |
265. Lipodystrophy
Clinical trials : 112 / Drugs : 155 - (DrugBank : 55) / Drug target genes : 25 - Drug target pathways : 97
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00656175 (ClinicalTrials.gov) | September 2008 | 2/4/2008 | Raltegravir Therapy for Women With HIV and Fat Accumulation | Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation | HIV Infections;Lipodystrophy | Drug: raltegravir | University of California, Los Angeles | Merck Sharp & Dohme Corp.;Case Western Reserve University;Vanderbilt University;Tufts University;University Health Network, Toronto | Completed | 18 Years | N/A | Female | 39 | Phase 2 | United States;Canada |
| 2 | NCT00135356 (ClinicalTrials.gov) | July 2005 | 25/8/2005 | Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome | A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing a Reyataz-Based Substitution Approach in the Management of Lipodystrophy Syndrome. Research Into Atazanavir in Lipodystrophy (The REAL Study) | HIV-Associated Lipodystrophy Syndrome | Drug: Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs);Drug: continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs) | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 219 | Phase 4 | United States;Canada;France;Germany;Italy;Mexico;Poland;Spain;United Kingdom;Netherlands |
| 3 | NCT00122668 (ClinicalTrials.gov) | November 2003 | 21/7/2005 | Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients | Randomized Comparative Study Evaluating the Rate of Occurrence of a Lipoatrophy Syndrome in ARVnaive HIV-1 Infected Patients Receiving NRTI-Sparing Antiretroviral Regimen (Hippocampe - ANRS 121) | HIV Infections;HIV-Associated Lipodystrophy Syndrome | Drug: non-nucleoside reverse transcriptase inhibitors;Drug: nucleoside reverse transcriptase inhibitors;Drug: protease inhibitor | French National Agency for Research on AIDS and Viral Hepatitis | NULL | Terminated | 18 Years | N/A | Both | 112 | Phase 4 | France |
| 4 | NCT00021463 (ClinicalTrials.gov) | April 2001 | 14/7/2001 | Changing to Nonprotease Inhibitor Treatment to Improve Side Effects | Phase II, Randomized, Open-Label Study of Switching to Protease Inhibitor-Sparing Regimens for Improvement of Metabolic Abnormalities | HIV Infections;Lipodystrophy | Drug: Abacavir sulfate, Lamivudine and Zidovudine;Drug: Abacavir sulfate;Drug: Efavirenz;Drug: Nevirapine | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Completed | 13 Years | N/A | Both | 342 | Phase 2 | United States |
| 5 | NCT00122655 (ClinicalTrials.gov) | January 2001 | 21/7/2005 | Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy | A Randomized Prospective Study Evaluating the Impact on Fat Distribution of NRTI-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy ANRS 108 NONUKE Study | HIV Infections;HIV Lipodystrophy Syndrome | Drug: non-nucleoside reverse transcriptase inhibitors;Drug: nucleoside reverse transcriptase inhibitors;Drug: protease inhibitors | French National Agency for Research on AIDS and Viral Hepatitis | NULL | Terminated | 18 Years | N/A | Both | 100 | Phase 4 | France |
| 6 | NCT00002417 (ClinicalTrials.gov) | March 1998 | 2/11/1999 | A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications | An Open-Label Study to Evaluate the Safety and Tolerance of Amprenavir (141W94) Combination Therapy in Protease Inhibitor Experienced Subjects Who Are Intolerant (Hyperlipidemia With or Without Lipodystrophy) But Not Failing Their Current Protease Inhibitor Therapy | HIV Infections | Drug: Amprenavir | Glaxo Wellcome | NULL | Completed | 13 Years | N/A | Both | N/A | United States |